Leap to continue supporting development of sirexatamab in DKK1-high CRC patients The DeFianCe study was a two part, open-label, multi-country study. Part A of the DeFianCe study enrolled 33 patients, ...
(RTTNews) - Shares of Leap Therapeutics Inc. (LPTX) are down over 60% at $0.83 in premarket trading Tuesday, following disappointing results from Part C of its DisTinGuish study. DisTinGuish is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results